Last reviewed · How we verify
NCT03330353: PMPSP
Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy
trial testing Pupillometry in PSP - Progressive Supranuclear Palsy in 56 participants. Status unknown.
1 October 2019
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 56 |
| Start date | 1 November 2017 |
| Primary completion | 1 October 2019 |
| Estimated completion | 1 October 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Pupillometry
Conditions studied
- PSP - Progressive Supranuclear Palsy — all drugs for PSP - Progressive Supranuclear Palsy →
- PD - Parkinson's Disease — all drugs for PD - Parkinson's Disease →
- AD - Alzheimer's Disease — all drugs for AD - Alzheimer's Disease →
- ALS (Amyotrophic Lateral Sclerosis) — all drugs for ALS (Amyotrophic Lateral Sclerosis) →
Sponsor
Massachusetts General Hospital
Who can join
55 and older, any sex, with PSP - Progressive Supranuclear Palsy or PD - Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The specific aim of this study is to investigate rod, cone and melanopsin driven pupillary light response in individuals with progressive supranuclear palsy (PSP), age-matched healthy controls and individuals with other neurodegenerative diseases using chromatic pupillometry, with special interest in assessing melanopsin-driven post-illumination pupil response (PIPR) as an identifier for PSP. The study addresses the following hypotheses: 1. Chromatic pupil responses, including rod/cone-driven rapid phase constriction and melanopsin-driven PIPR, are reduced in subjects with PSP compared to age-matched normal healthy control subjects, 2. Pupil parameters of the melanopsin-driven PIPR are abnormal in PSP subjects without supranuclear palsy, which is indicative of a subclinical physiological deficit of the OPN in the early stages of PSP. If these hypotheses are upheld, chromatic pupillometry to measure the PIPR promises to be a reliable in vivo, non-invasive, convenient and inexpensive technique to detect asymptomatic pupillomotor impairment in advance of diagnostic oculomotor signs and deterioration of cognitive function.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ocular Manifestations of Alzheimer's and Other Neurodegenerative Diseases: The Prospect of the Eye as a Tool for the Early Diagnosis of Alzheimer's Disease.
Colligris P, Perez de Lara MJ, Colligris B, Pintor J. · · 2018 · cited 54× · PMID 30151279 · DOI 10.1155/2018/8538573
Verify or expand the search:
- PubMed search for NCT03330353
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pupillometry
Trials testing the same drug.
- NCT05829044 — Impact of Sex and Age on Non-visual Light Input That Affects Sleep and Circadian Rhythms · NA · recruiting
- NCT05962996 — Evaluation of Pain Levels by Quantitative Pupillometry During the Placement of Deep Venous Catheters in Sedated Patients · unknown
- NCT04947397 — Investigation of Pupillometry as Guide for Extubation Readiness in Anesthetized Children · NA · completed
- NCT04742790 — QSPainRelief-patientCNS : Clinical Biomarkers of Nociception, Sedation and Cognition · NA · unknown
- NCT03862222 — Atlas of Retinal Imaging in Alzheimer's Study · completed
Other recruiting trials for PSP - Progressive Supranuclear Palsy
Currently open trials in the same condition.
- NCT06647641 — The CurePSP Genetics Program · recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03330353 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 7 November 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03330353.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing